|
Synonyms: EBI-005
Compound class:
Peptide or derivative
Comment: Isunakinra (EBI-005) is a fusion protein containing domains from IL-1β and IL-1 receptor antagonist (IL-1Ra or anakinra) [3]. It potently blocks IL-1R1 signalling, with higher affinity than anakinra. It was developed as a topical therapy for inflammatory diseases of the ocular surface.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Isunakinra reached Phase 3 clinical trials for dry eye disease (see NCT02405039) and severe ocular allergic conjunctivitis. Earlier trial results had indicated that isunakinra was safe and well tolerated, and showed clinically meaningful improvements in signs and symptoms of dry eye disease [2]. Significant clinical benefit was not evident from analysis of results from the Phase 3 ocular allergic conjunctivitis trial (NCT02492321), and development does not appear to have progressed. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02405039 | Study of EBI-005 in Dry Eye Disease (DED) | Phase 3 Interventional | Eleven Biotherapeutics | ||
| NCT02492321 | A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis | Phase 3 Interventional | Eleven Biotherapeutics | ||
